Will experience support use of first-ever retinal gene therapy?
by: Maximilian J. Gerhardt, MD Recent reports of retinal atrophy have raised concerns on potential long-term safety. Voretigene neparvovec (Luxturna, Spark Therapeutics) is the first causal treatment for biallelic RPE65 mutation–associated…